Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Baseline characteristics … - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Baseline characteristics and the effects of two years of growth hormone replacement therapy in adults with growth hormone deficiency previously treated for Cushing's disease.

Artikel i vetenskaplig tidskrift
Författare Gudmundur Johannsson
Katharina S Sunnerhagen
Johan Svensson
Publicerad i Clinical endocrinology
Volym 60
Nummer/häfte 5
Sidor 550-9
ISSN 0300-0664
Publiceringsår 2004
Publicerad vid Institutionen för klinisk neurovetenskap
Institutionen för invärtesmedicin
Sidor 550-9
Språk en
Länkar dx.doi.org/10.1111/j.1365-2265.2004...
Ämnesord Body Composition, drug effects, Bone Density, drug effects, Cushing Syndrome, physiopathology, therapy, Densitometry, X-Ray, Female, Hormone Replacement Therapy, Human Growth Hormone, deficiency, therapeutic use, Humans, Hypopituitarism, drug therapy, Male, Middle Aged, Muscle, Skeletal, physiopathology, Prospective Studies, Recombinant Proteins, therapeutic use, Statistics, Nonparametric
Ämneskategorier Endokrinologi

Sammanfattning

OBJECTIVE: To determine baseline characteristics and the effects of 2 years of GH replacement therapy on body composition, muscle strength, bone mass, and metabolic indices in GH-deficient (GHD) adults previously treated for pituitary-dependent Cushing's disease. DESIGN: A single-centre, open-labelled, prospective study. PATIENTS: Fifteen consecutive GHD adults previously treated for pituitary-dependent Cushing's disease (CD group) and 15 closely matched GHD adults with previous nonfunctioning hypopituitary disease (NF group) were included. All patients had adult-onset GH deficiency. RESULTS: The mean dose of GH was similar in both study groups during the 2-year treatment. At baseline, diastolic blood pressure was higher, and lumbar (L2-L4) bone mineral density (BMD) was lower, in the CD group than in the NF group. The increase in lean mass in response to GH therapy, as measured by dual-energy X-ray absorptiometry (DEXA), was less marked in the CD group. GH replacement therapy reduced diastolic blood pressure only in the CD group. The patients in the CD group had greater treatment response in lumbar (L2-L4) spine BMD and in isometric and isokinetic knee extension strength than the patients in the NF group. At study end, no difference remained between the two study groups. CONCLUSIONS: This study revealed differences in the baseline characteristics between GHD patients previously treated for Cushing's disease as compared with closely matched GHD patients with previous nonfunctioning hypopituitary disease. The 2-year GH replacement therapy eliminated all the differences between the two study groups.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?